X-linked hypophosphatemia, or XLH, is a rare genetic bone disorder that can affect children’s development when not detected early. Limited awareness, high screening costs, and uneven access to specialist care often delay diagnosis.
In collaboration with the Thai Society for Pediatric Endocrinology, the Thai Rare Disease Foundation, and the XLH Community, DKSH supported “XLH Day” in Bangkok. The initiative brought together healthcare professionals, caregivers, and advocates to share insights on early symptoms, diagnostic pathways, and evolving approaches to care.
Treatment options for XLH have progressed, including vitamin D, phosphate supplementation, and anti‑FGF23 therapy, which patients have reported to significantly improve mobility, bone density, and overall quality of life. The expected shift from phosphate syrup to more convenient tablets will also support better treatment consistency for children.
We are proud to work alongside the Thai Society for Pediatric Endocrinology and other partners to strengthen awareness and support for XLH. Through purposeful collaboration and continued efforts to expand access to care, treatment options and medical innovation for rare diseases, we aim to help improve support systems for communities living with rare diseases and foster greater understanding of their long-term impact.
At DKSH, our purpose is to enrich people’s lives. We do so by providing reliable access to high-quality and responsible products and services, creating sustainable value for our partners, and contributing to raising the quality of life in the communities we operate in by generating jobs, perspectives, and opportunities for people’s development and growth.